Keywords: Affymax, Takda, Peginesataide, Milestone, NDA, Hematide, Kidney disease, Anemia, Second-quarter results
Affymax gets $10 million milestone from Takeda on peginesatide NDA acceptance
Article | 11 August 2011
California, USA-based Affymax (Nasdaq: AFFY) says it has received a $10 million development milestone payment from Takeda Pharmaceutical (TYO: 4502), Japan’ ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
